|
Pulmonx Corporation (NASDAQ: LUNG) |
|
Pulmonx Corporation
LUNG's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Pulmonx growth rates, revenue grew
by 26.4 % in IV. Quarter 2024 from the same quarter a year ago.
Ranking at No. 674
Medical Equipment & Supplies industry recorded
deterioration of revenues by -0.3 %
Pulmonx net loss decreased from $-14 millions, to $-13 millions in IV. Quarter 2024,
• More on LUNG's Growth
|
|
Pulmonx realized a net loss in trailing twelve months.
Pulmonx realized cash reduction of $ -0.32 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 2.45.
Medical Equipment & Supplies industry's Price to Sales ratio is at 4.12.
• More on LUNG's Valuation
|
|
|
|
|
Pulmonx realized net loss in trailing twelve months.
Pulmonx realized cash outflow of $ -0.32per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 2.45.
Medical Equipment & Supplies industry's Price to Sales ratio is at 4.12.
Pulmonx Price to Book Ratio is at 2.37 higher than Industry Avg. of -460.18, and higher than S&P 500 Avg. of 0.01
• More on LUNG's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com